- Desjeux P.Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis2004;27: 305–318.
- Gil-Prieto R, Walter S, Alvar J, de Miguel AG.Epidemiology of leishmaniasis in Spain based on hospitalization records (1997–2008). Am J Trop Med Hyg2011;85: 820–825.
- Sinha PK, van GJ, Pandey K et al.Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis2011;53: e91–e98.
- ter Horst R1, Tefera T, Assefa G, Ebrahim AZ, Davidson RN, Ritmeijer K.Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am J Trop Med Hyg2009;80: 929–934.
- Gu Y, Ma CH, Zhou LB. [A HIV antibody-positive patient with kala azar.] Shi Yong Yi Ji Za Zhi2008;16: 2156–2157.Chinese.
- Bao YX, Pan KJ, Mai MT et al. [One case of AIDS with kala-azar.] Zhong Guo Bing Du Bing Za Zhi2012;6: 75–76.Chinese.
- Xia HJ, Yi YJ, Liao YQ. [The analysis of misdiagnosis about three cases of kala-azar with HIV infection.] Zhong Guo Pi Fu Xing Bing Xue Za Zhi2011;7: 567–568.Chinese.
- Zhang GJ, Cao BL, Xing JY. [One case with HIV infection and kala-azar.] Pi Fu Xing Bing Xue Za Zhi2010;11: 1072–1074.Chinese.
- Jarvis JN, Lockwood DN.Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis2013;26: 1–9.
- Hurissa Z, Gebre-Silassie S, Hailu W et al.Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health2010;15: 848–855.
- Ritmeijer K, Dejenie A, Assefa Y et al.A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis2006;43: 357–364.
- Hailu W, Weldegebreal T, Hurissa Z et al.Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg2010;104: 706–712.
- Chakravarty J, Sundar S.Drug resistance in leishmaniasis. J Glob Infect Dis2010;2: 167–176.
- Sundar S, More DK, Singh MK et al.Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis2000;31: 1104–1107.
- Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R.Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg2002;66: 143–146.
- Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis2004;38: 377–383.
- Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med2010;362: 504–512.
- Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R.Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg2007;101: 19–24.
- Sundar S, Singh A, Rai M et al.Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis2012;55: 543–550.
- Sundar S, Rosenkaimer F, Makharia MK et al.Trial of oral miltefosine for visceral leishmaniasis. Lancet1998;352: 1821–1823.
- Gui XE, Guan LR. [Differential diagnosis of visceral leishmaniasis, progressive disseminated histoplasmosis and penicilliosis marneffei.] Zhong Guo Ji Sheng Chong Xue He Ji Sheng Chong Bing Za Zhi2007;25: 69–72.Chinese.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research